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Objective: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no
reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described.
Design:We report the complex clinical presentation of the unique case, never described, of acromegaly due to
GH-secreting pituitary adenoma associated with JAK2 V617F mutation.
Results: The patient shows primary thrombocythemia and myeloﬁbrosis, due to JAK2 V617F mutation, severe
visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1
during somatostatin analog (SA) treatment despite a signiﬁcant reduction in pituitary adenoma size and
therapeutic resistance both to SA and pegvisomant.
Conclusions: The presence of JAK2 V617F mutation is a cause of primary thrombocythemia and myeloﬁbrosis
in acromegaly. In this patient, a peculiar clinical course of acromegaly was observed, with the difﬁculty in
controlling the disease. More data, on a larger cohort of patients, could clarify whether JAK2 V617F mutation
has a serious impact on the clinical features and course of acromegaly.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Growth hormone (GH) actions are mediated via the GH receptor
(GHR) and their interaction leads to phosphorylation of the tyrosine
residues of Janus kinase (JAK) 2, with subsequent phosphorylation
of signal transducers and activators of transcription (STATs) and
activation of Ras mitogen-activated-protein kinase pathways [1,2].
In 2005, Kralovics et al. reported the results of an analysis of the
JAK2 gene in patients with myeloproliferative neoplasms, observing
a dominant gain-of-function mutation in which valine at position
617 was replaced by phenylalanine (V617F) in the majority of
patients [3]. This mutation identiﬁes a subset of patients affected by
essential thrombocythemia and polycythemia verawhoare predisposed
to thrombosis and myeloﬁbrosis, and appears to render hemopoietic
cells more sensitive to growth factors [4]. The prevalence and clinical
signiﬁcance of JAK2 V617F in the general population is unknown and
it may also be prevalent in individuals without overt signs of myelopro-
liferative cancer [5,6]. The excessive chronic activation of the GHR-JAK2
pathway by high circulating levels of GH results in acromegaly, whereas
cell transformation and cancer can occur in response to autocrine activa-
tion of the receptor. In acromegaly, an increased prevalence of hemato-
logical abnormalities and lymphohematopoietic neoplasms is described,
including polycythemia vera, lymphoma, multiple myeloma, chronic
myelogenic or lymphocytic leukemia [7-10], but to date there are no
reports describing the presence of the JAK2 mutation in acromegaly.
Similarly, no data about GH and IGF-1 levels and their feedback regula-
tion in non-acromegalic patients that are carriers of the JAK2 mutation
are available in the literature. On the other hand, several studies have
reported a varying prevalence of discrepancy between GH and IGF-I
concentrations in acromegalic patients both at diagnosis and during
the follow-up. The mechanisms underlying this discordance have not
been fully explored [11-14], although it has been proposed that factors
such as age, gender, prior radiotherapy and the GHR polymorphism
may be able to modify the relationship between GH and IGF-I [15-18].
We report the unique case of an acromegalic patient with JAK2 V617F
mutation and the clinical and hormonal consequences of these two
associated conditions.
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2. Materials and methods
2.1. Clinical parameters
A 72-year-old man, a former smoker, was admitted 18 months ago
to our Endocrine Unit because of recent evidence of weakness and
dyspnea after exercise and fasting hyperglycemia. Table 1 shows the
patient's clinical features. He complained of having had headache,
diffuse arthralgia, nocturnal polyuria and slight dysphagia for at
least 1 year. At clinical examination he had seborrheic skin and hair,
high levels of systolic and diastolic blood pressure (170 and 95 mm
Hg, respectively) and arrhythmic heart rate (78 bpm). No signiﬁcant
change in weight was reported. Prognathism, macroglossia, large
hands and feet and multinodular goiter were detected.
2.2. Biochemical and instrumental parameters
Routine laboratory tests showed high platelet count (682×109/L;
normal value 150–450) and normocytic anemia. Basal hormonal
evaluation revealed normal thyroid hormones, elevated IGF-I
(918 μg/L, age and sex-matched normal 78–200) and high mean
basal GH levels (37 μg/L), with absence of GH suppression to the oral
glucose tolerance test (OGTT) (GH nadir 7.68 μg/L). The remaining
pituitary function was normal. OGTT showed frank diabetes mellitus
with hyperinsulinism (serum insulin peak during OGTT 212 IU/ml)
and glycosylated hemoglobin (HbA1c) level was 7.5%. A magnetic res-
onance imaging (MRI) scan showed a pituitary macroadenoma
(tumor volume 2.59 cm3). Two indications of positivity for fecal occult
blood test samples, high levels of carcinoembryonic antigen (CEA),
colonscopy ﬁnding of multiple colorectal adenomatous polyps and
contextual biopsy led to the diagnosis of tubular adenoma with low-
grade dysplasia. Visual ﬁeld evaluation showed normal ﬁndings.
Concentric biventricular hypertrophy with normal ejection fraction
was detected by echocardiography. Ultrasonic evaluation showed an
increase in carotid intima-media thickness with multiple carotid
plaques and amultinodular goiter,while computerized axial tomography
showed severe visceromegaly, with increased spleen, liver, bile ducts and
Wirsung size, multicystic dysplastic kidneys, a pancreatic cyst of 30 mm
and a left adrenal nodule of 15 mm (Fig. 1). High platelet count having
been conﬁrmed (639×109/L), after consulting with hematologists the
analysis of the JAK2 gene was performed and the presence of the V617F
mutation was conﬁrmed. The patient underwent osteomedullary biopsy
of the iliac crest and evidence of 40% bonemarrow cellularitywithmega-
karyocytic hyperplasia and increasedmedullaryﬁbrosis led to a diagnosis
of primary myeloﬁbrosis.
We administered metformin, sartan, aspirin and octreotide long
acting release (LAR) as ﬁrst-linemedical treatment, with intramuscular
injections of 20 mg every 28 days.
2.3. Detection of JAK2 V617F mutation
Genomic DNA was extracted from whole unfractionated peripheral
blood samples according to the instructions contained in the QIAamp
Blood Kit (Qiagen, Hilden, Germany). 25 ng of sample genomic DNA
was added to the ampliﬁcation mixture using the JAK2 MutaScreen
assay (Ipsogen, Luminy Biotech, Marseille, France) on ABI PRISM 7900
(Applied Biosystems, Foster City, CA). This assay is based on the use of
2 speciﬁc TaqMan probes and the measurement of the respective
ﬂuorescence of the 2 alleles (FAM for V617F and VIC for wild-type) to
differentiate the ampliﬁcation of each allele. The mean ratio of mutant
to wild-type allele was calculated for patient sample andwas compared
with the mean ratio of the reference sample provided.
Table 1
Clinical and biochemical features of patient at diagnosis and during the treatment. LAR: octreotide-long acting release; PEG-V: pegvisomant.
Symptoms and signs at diagnosis
Weakness
Dyspnea
Headache
Diffuse arthralgia
Dysphagia
Seborrheic skin and hair
Prognathism
Macroglossia
Enlarged hands and feet
Diabetes mellitus
Hyperinsulinemia
Systolic and diastolic hypertension
Cardiac arrhythmia
Multinodular goiter
Multiple colorectal polyps
Cardiac hypertrophy
Atherosclerosis
Hepatomegaly
Splenomegaly
Multicystic kidneys
Pancreatic cyst
Nodular adrenal hyperplasia
Biochemical parameters
Pre-treatment After 6 months
of LAR 20 mg
After 4 months
of LAR 30 mg
After 3 months
of PEG-V 10 mg
After 3 months
of PEG-V 15 mg
After 1 month
of PEG-V 20 mg
Platelet count (n.v.150–450) 682×109/L 651×109/L 612×109/L – – –
IGF-I (μg/L) (n.v. 78–200) 918 715 750 610 590 601
Mean basal GH (μg/L) 37 4.5 2.2 – – –
GH nadir (after OGTT) (μg/L) 7.68 1.2 0.3 – – –
HbA1c (%) (n.v. b 5.5) 7.5 7.3 7.4 7.7 7.4 7.5
Tumor volume (cm3) 2.59 – 1.76 – – –
n.v.: normal value.
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2.4. Hormone and biochemical assays
Serum GH levels were determined by immunoradiometric assay
(IRMA) (Immulite; Diagnostic Products Corp., Los Angeles, CA), with
an assay sensitivity of 0.05 μg/L. Serum IGF-1 was measured using
IRMA (Diagnostic System Laboratories Inc., Webster, TX), with an
assay sensitivity of 0.8 μg/L. The normal range for age and sex was
78–200 μg/L. Hemochromewasmeasured in our centralized laboratory
with standard methods. The normal value for platelet count is
150–450×109/L.
3. Results
3.1. 6 months-follow-up
After the ﬁrst 6 months of monthly LAR 20 mg, the patient showed
only a slight reduction in HbA1c levels (7.3 vs. 7.5%), without beneﬁt
for the platelet count (651×109/L) and no full normalization of
hormonal parameters (basal GH 4.5 μg/L, GH nadir 1.2 μg/L IGF1-1
715 μg/L). Because of IGF-1 being persistently above the normal
range, despite signiﬁcantly decreased basal GH levels, the dose of
octreotide-LAR was increased to 30 mg/month.
3.2. 10 months-follow-up
After another 4 months of treatment, IGF-1 was still above the
normal range (750 μg/L), but with concomitant “safe” mean basal
(2.2 μg/L) and nadir GH (0.3 μg/L). The platelet count remained high
(612×109/L) and HbA1c above the normal range (7.4%) despite the
full dose of metformin, while MRI showed a 32% decrease in tumor
mass (1.76 vs. 2,59 cm3) (Fig. 2). Based on persistent high IGF-1
levels, octreotide therapy was stopped and the patient started
pegvisomant (PEG-V) treatment at an initial daily dose of 10 mg,
increased to 15 mg after 3 months because of failure to achieve the
target IGF-1 level (610 μg/L).
3.3. 16–17 months-follow-up
Recently, after another 3 months with a daily dose of 15 mg, due
to evidence of IGF-1 being well above the normal range (590 μg/L),
we increased the daily dose of PEG-V to 20 mg, but after 30 days of
treatment a slight elevation of serum concentrations of alanine
aminotransferase and aspartate aminotransferase, not greater than
twice the upper limit of normal, was observed, with concomitant
lack of decrease in IGF-1 (601 μg/L). Notably, HbA1c levels remained
well above the normal range also after the start of PEG-V treatment
(7.7%, 7.4% and 7.5% after daily dose of 10, 15 and 20 mg,
respectively).
Table 1 shows the patient's biochemical features during the treat-
ments. The graphic representation of GH and IGF-1 levels is shown in
Fig. 3. The follow-up of the disease is ongoing.
4. Discussion
In acromegaly, an increased risk of hematological abnormalities
and lymphohematopoietic neoplasms is described as a secondary
manifestation of the disease and usually regresses after the disease
is treated [7,19]. By contrast, primary hematological abnormalities
in acromegaly are rarely reported on nor, to date, have the presence
of the JAK2 V617F mutation, known as a cause of essential thrombo-
cythemia and polycythemia vera, ever been reported on. JAK2 V617F
mutation is observed in about 60–65% of patients with essential
thrombocythemia. In these patients, because signaling by themutated
kinase utilizes normal pathways, the result is an overproduction of
Fig. 1. Severe visceromegaly detected by computerized axial tomography: multicystic dysplastic kidneys (A); multicystic liver (B); increased bile ducts size (C); 15-mm left adrenal
nodule (D); increased Wirsung size (E); 30-mm pancreatic cyst (F).
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Fig. 3. Graphic representation of divergence between GH and IGF-1 levels during the treatment with different doses of octreotide LAR and Pegvisomant.
Fig. 2. MRI showing pituitary adenoma at diagnosis (2.59 cm3) and after 10 months of octreotide LAR (1.76 cm3).
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morphologically normal blood cells, an often indolent course and
usually a normal lifespan [20]. In about 30% of cases the mutation is
accompanied by thromboembolic events [21], but in JAK2 negative
cases thrombotic events could also be detected and the incidence of
thrombosis ensuing in JAK2 negative cases does not differ signiﬁcantly
from JAK2 positive patients. The clinical features of these patients are
not speciﬁc, and could include an increased prevalence in marrow
ﬁbrosis and splenomegaly [20], while platelet count and platelet
function tests seem not to be inﬂuenced by JAK2 V617F positivity
[22]. Indeed, no difference in platelet count seems to exist between
patients affected by essential thrombocythemia with and without
JAK2V617F mutation. In the present case, thrombocythemia repre-
sents a primary disease in an acromegalic patient due to the mutation
in the JAK2 gene, does not differ from essential thrombocythemia and
does not return to normal during acromegaly treatment. In our
patient, whether the JAK2 V617F is to be considered as a primary
mutation or one secondary to the smoking history is not known.
Indeed, accelerated erythropoiesis does seem to render the cells
more susceptible to JAK2 mutation among smokers than nonsmokers
[23]. Whether the main clinical features of the patient, represented by
the severe visceromegaly and difﬁculty in controlling the disease, are
affected by the presence of JAK2 V617F is unclear. In the literature,
divergence between GH and IGF-I values are often reported in acro-
megalic patients, both at diagnosis and during treatment, but the
mechanisms of this discrepancy have not been completely explored
[24,25]. When discrepant results are present, the treatment is usually
adjusted on the basis of IGF-1 levels [26]. In patients with persistently
elevated IGF-1 levels despite high SA doses, GH receptor antagonist
can be used. PEG-V exerts its action peripherally by blocking GH action
rather than centrally, as happens with SA, leading to reduced IGF-1
production in acromegalic patients resistant to SA [27-29]. Different
factors, such as circulating estrogens, age or prior radiotherapy may
be involved in the GH/IGF-I divergence [15-17]. The impact of GHR
polymorphism on the prevalence of discordant levels of GH and IGF-
I has also been proposed [30]. In addition, among the discrepant
patients, the high “IGF-1 phenotype” seems to be associated with a
worsemetabolic proﬁle [31,32] and this could explain the poor control
of diabetes, despite the full dose of metformin and the start of PEG-V
treatment, in our patient. In this single case, the impact of GHR
autocrine activation and its signal transduction on the post-treatment
biochemical assessment of acromegaly remains to be proven. JAK2
V617F is a somatic mutation and all reports to date indicate it is
conﬁned to myeloid cells. No data about the presence of JAK2 V617F
in non-myeloid cells are available in the literature. Therefore, the
mutation should have little impact on liver-produced IGF-I. On the
other hand, no data about IGF-1 levels in non-acromegalic patients
that are carriers of the JAK2mutation, nor evidence of IGF-1 production
from constitutively activated myeloid cells, are available. We are aware
that we are reporting just one clinical case of association between the
presence of JAK2 V617F mutation and a peculiar clinical course of
acromegaly, but we consider it of interest being the ﬁrst case ever
described of two rare and interesting conditions. Whether this associa-
tion is casual or causal remains to be proven. More data, on a larger
cohort of patients, could suggest that genetic analysis may be helpful
in understanding more severe cases of acromegaly and could clarify
whether JAK2 V617F mutation has a serious impact on the clinical
features and course of acromegaly.
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